[Prostatic cancer in the male under age 60].
Staging, therapy and course of disease in 32 patients with carcinoma of prostate less than 60 years old were evaluated retrospectively, 87.5% of the men showed metastases before commencement of therapy. Not one case of cancer was detected during preventive check up; all patients come to urological examination because of characteristic symptoms.33.3% of carcinomas were primarily hormone-resistant. Under pure androgen deprivation (n = 21) 81% of the patients showed progression within a mean period of 9.2 months, whereas in the small group primarily given combined contrasexual cytostatic therapy (n = 5) progression occurred after a time span of 39 months on average. The importance of preventive urological examination and the possibility of primary cytostatic therapy in combination with androgen deprivation in young patients with metastatic cancer of the prostate is stressed.
Maier
U
U
Urologische Universiätsklinik, Wien.
Nuehold
N
N
D000328:Adult; D000726:Androgen Antagonists / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004961:Estramustine / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000628:therapy*
D000726:Androgen Antagonists; D004961:Estramustine
Das Prostatakarzinom beim Mann unter dem 60. Lebensjahr.